GI Dynamics, Inc. (ASX: GID) have announced that it has initiated its U.S. multicenter pivotal clinical trial of EndoBarrier®, the ENDO Trial, for the treatment of patients who have uncontrolled type 2 diabetes and are obese.
Read more
-
-
Recent Posts
-
-